Please assess the completion status of the following clinical trial:

Trial Title: Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Is ≧ 18 years of age on the day of signing informed consent or other age required by local regulation~2. Willing and able to provide written informed consent~3. ESRD patients who is undergoing hemodialysis 3 times per week and is considered necessary to receive medication for hyperphosphatemia by his/her treating physician~4. Serum ferritin \<1000 ng/mL and transferrin saturation (TSAT) \< 50% at the Enrollment Visit~5. Women of child-bearing potential (WOCBP \[defined as women ≤ 50 years of age with a history of amenorrhea for \< 12 months prior to study entry\]) who is willing to use an effective form of contraception during study participation~Exclusion Criteria:~1. Has any known contraindication to ferric citrate according to locally approved prescribing information, include but not limited to the following criteria:~   i. Is allergic to ferric citrate ii. Has hypophosphatemia iii. Has hemochromatosis or iron overload syndromes iv. Has active severe GI disorders~2. Has parathyroidectomy (PTx) or percutaneous ethanol injection therapy (PEIT) within 3 months prior to Enrollment Visit or serum calcium \< 7 mg/dL at the Enrollment Visit~3. Has participated in another interventional study for any investigational agent or device within 30 days prior to enrollment~4. Is currently pregnant or breastfeeding~5. Other unstable medical condition or psychiatric conditions that is considered unsuitable for this study per Investigator's clinical judgment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric citrate (Type: EXPERIMENTAL): Ferric Citrate (Nephoxil® Capsules) will be dosed three times a day (with meals).

Based on this trial design, predict the completion outcome and termination type (if applicable).